A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis

Hematology

Volumn 16, Issue 6, 2011, Pages 327-336

  van Geffen, Mark ^a   Loof, Arnoud ^a   Lap, Paul ^a   Boezeman, Jan ^a   Laros van Gorkom, Britta A P ^a   Brons, Paul ^a   Verbruggen, Bert ^a   van Kraaij, Marian ^b   van Heerde, Waander L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sanquin Blood Bank South East ^*  (Netherlands)

Author keywords

Fibrinolysis; Hemostasis; Plasmin; Thrombin generation; Thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; BATROXOBIN; GLYCYLPROLYLARGINYLPROLINE; HEPARIN; HIRUDIN; PEPTIDE DERIVATIVE; PLASMIN; PROTEIN C; PROTHROMBIN; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME KINETICS; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IN VITRO STUDY; NOVEL HEMOSTASIS ASSAY; OBSERVER VARIATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN FUNCTION; REGULATORY MECHANISM; THROMBIN TIME; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; FIBRINOLYSIN; FIBRINOLYSIS; HEMOSTASIS; HEPARIN; HUMANS; KINETICS; MALE; MIDDLE AGED; PHOSPHATIDYLETHANOLAMINES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE; SUBSTRATE SPECIFICITY; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 82955164016     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X13085644680348     Document Type: Article

References (40)

1. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-24.
2. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003;1:551-8.
3. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296:397-402.
4. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007;138:769-74.
5. Dargaud Y, Beguin S, Lienhart A, Al DR, Trzeciak C, Bordet JC, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005;93:475-80.
6. Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989;61:25-9.
7. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in plateletrich plasma. Thromb Haemost 2000;83:589-91.
8. Wagenvoord RJ, Hendrix HH, Kai H, Hemker HC. A chromogenic test to determine the procoagulant phospholipids in platelet-rich plasma and whole blood. Thromb Haemost 1994;72:582-7.
9. Tappenden KA, Gallimore MJ, Evans G, Mackie IJ, Jones DW. Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism. Br J Haematol 2007;139:106-12.
10. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9:168-73.
11. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-9.
12. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Jr, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985;64:888-96.
13. Kakkar T, Boxenbaum H, Mayersohn M. Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab Dispos 1999;27:756-62.
14. Sorensen B, Asvaldsdottir HS, Gudmundsdottir BR, Onundarson PT. The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery. Thromb Res 2009;124:695-700.
15. Viuff D, Andersen S, Sorensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res 2010;126:144-9.
16. Szlam F, Levy JH, Tanaka KA. Tissue plasminogen activator and thrombin generation measurements using the Thrombinoscope. Blood Coagul Fibrinolysis 2006;17:603-4.
17. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004;2:416-23.
18. van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissuetype plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J Biol Chem 1986;261:14214-8.
19. Gallistl S, Muntean W, Zenz W. Gly-pro-arg-pro (GPRP) enhances free thrombin. Thromb Res 1995;78:547-50.
20. Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008;34:670-82.
21. He S, Zhu K, Skeppholm M, Vedin J, Svensson J, Egberg N, et al. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost 2007;98:871-82.
22. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005;116:345-56.
23. Spiess BD, Logas WG, Tuman KJ, Hughes T, Jagmin J, Ivankovich AD. Thromboelastography used for detection of perioperative fibrinolysis: a report of four cases. J Cardiothorac Anesth 1988;2:666-72.
24. Yamakage M, Tsujiguchi N, Kohro S, Tsuchida H, Namiki A. The usefulness of celite-activated thromboelastography for evaluation of fibrinolysis. Can J Anaesth 1998;45:993-6.
25. Butenas S, van't VC, Mann KG. 'Normal' thrombin generation. Blood 1999;94:2169-78.
26. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74:134-8.
27. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000;84:747-51.
28. Rijken DC, Hoegee-de NE, Jie AF, Atsma DE, Schalij MJ, Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 2008;6:151-7.
29. Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res 2011;127:317-23.
30. Schmaier AH, McCrae KR. The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 2007;5:2323-9.
31. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009;7(Suppl 1):84-7.
32. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-81.
33. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010;116:3981-9.
34. Ogiwara K, Nogami K, Nishiya K, Shima M. Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. Blood Coagul. Fibrinolysis 2010;21:568-76.
35. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 1991;83:937-44.
36. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombinactivable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004;279:27896-904.
37. Broze GJ, Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996;88:3815-23.
38. Wagenvoord RJ, Deinum J, Elg M, Hemker HC. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha(2)-macroglobulin-thrombin. J Thromb Haemost 2010;8:1281-9.
39. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973;133:709-24.
40. Salvesen GS, Barrett AJ. Covalent binding of proteinases in their reaction with alpha 2-macroglobulin. Biochem J 1980;187: 695-701.